August 14, 2024 02:28 PM EDTUpdated August 16, 01:09 PM

Arrowhead lays out early-stage obesity strategy, including new target on fat-storing cells

Nicole DeFeudis

Editor

Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be “gentler” than currently available GLP-1 products …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arrowhead lays out early-stage obesity strategy, including new target on fat-storing cells

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

Charles River to lay off 3% of staffers as it streamlines spending

Seres' microbiome therapy reduces infections in stem cell transplant patients, but next steps are unclear

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Ar­row­head lays out ear­ly-stage obe­si­ty strat­e­gy, in­clud­ing new tar­get on fat-stor­ing cells

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Arrowhead lays out early-stage obesity strategy, including new target on fat-storing cells